Vaccines, Therapies and the Need for Speed: Experts to Discuss the Fight Against Covid-19
Darmstadt, Germany, September 8, 2020 OpinePR 🎯 — How quickly can a vaccine be developed for Covid-19? As people around the world wait for therapies and viable vaccines, an expert panel will discuss how to safely and effectively accelerate clinical trials.
During the fourth in a series of live, virtual Pandemic Response Catalyst Conversations, five leading scientific experts will provide facts and insights on today’s antiviral and vaccine candidate clinical trial data and discuss new testing methods. Discussion will also include strategies to deliver on the global investment in rapid development through open science and unified standards.
Media representatives are invited to join the event, which will include a question and answer session. This six-part series is hosted by the Life Science business of Merck, the Massachusetts Institute of Technology’s (MIT) Center for Collective Intelligence and MIT Media Lab’s Community Biotechnology Initiative.
· David Onions, independent vaccine safety consultant.
WHAT: The Pandemic Response Catalyst Conversation series is part of an initiative developed by the three host organizations to generate open science and data-driven, collaborative solutions.
WHEN: Thursday, September 17, 2020 at 4 p.m. CDT.
Interview opportunities available by emailing firstname.lastname@example.org.
WHERE: Streamed via Livestream.com.
About the MIT Center for Collective Intelligence
The MIT Center for Collective Intelligence brings together faculty from across MIT to conduct research on how new communications technologies are changing the way people work together. This first-of-its-kind research effort draws on the strengths of many diverse organizations across the Institute including the MIT Media Lab, the Computer Science and Artificial Intelligence Laboratory, the Department of Brain and Cognitive Sciences, and the MIT Sloan School of Management.
For more information, visit https://cci.mit.edu/.
About the MIT Community Biotechnology Initiative
The MIT Community Biotechnology Initiative (CBI) of the MIT Media Lab develops tools and technologies to enable the broadest possible participation in biotechnology. Projects include the creation of low-cost enabling hardware, infrastructure for sharing, and new interfaces for artistic expression with biology.
For more information, visit https://www.media.mit.edu/groups/community-bio/overview/.
Merck, a leading science and technology company, operates across healthcare, life science and performance materials. Around 57,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene-editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – Merck is everywhere. In 2019, Merck generated sales of €16.2 billion in 66 countries.
Scientific exploration and responsible entrepreneurship have been key to Merck’s technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the “Merck” name and brand. The only exceptions are the United States and Canada, where the business sectors operate as EMD Serono in healthcare, MilliporeSigma in life science and EMD Performance Materials.